{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:58:53Z","timestamp":1759334333492,"version":"build-2065373602"},"reference-count":5,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"3","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>\u00a0\nAntecedentes: Las reacciones de hipersendibilidad a anticuerpos monoclonales representan un desaf\u00edo cl\u00ednico, especialmente cuando no existen alternativas terap\u00e9uticas equivalentes. Brentuximab vedotina (BV), anticuerpo monoclonal anti-CD30 indicado para el linfoma de Hodgkin en reca\u00edda, se ha asociado con hipersensibilidad inmediata en 1.2% de los casos.\nResporte de caso cl\u00ednico: Paciente de 11 a\u00f1os con linfoma de Hodgkin en reca\u00edda, quien durante el 5\u00ba ciclo de quimioterapia con AVD (doxorrubicina, vinblastina y dacarbazina) + BV present\u00f3 anafilaxia grado 3 (escala de Brown) con hipotensi\u00f3n, disnea, tos, sibilancias, edema bipalpebral, inyecci\u00f3n conjuntival, n\u00e1useas y alteraci\u00f3n del estado de conciencia. Se administr\u00f3 epinefrina intramuscular y fluidoterapia, con resoluci\u00f3n del cuadro. Estudios de laboratorio: Pruebas cut\u00e1neas a BV realizadas 2 semanas despu\u00e9s del evento fueron negativas. Evoluci\u00f3n: Dada la inmediatez y gravedad del evento, y la necesidad de continuar con el tratamiento, se realiz\u00f3 reto farmacol\u00f3gico exitoso con los agentes AVD. Posteriormente, se llevaron a cabo dos ciclos de desensibilizaci\u00f3n a BV (ciclos 6\u00ba y 7\u00ba), utilizando diferentes protocolos, sin reacciones adversas.\nConclusi\u00f3n: Aunque las pruebas cut\u00e1neas fueron negativas, la cl\u00ednica fue compatible con hipersensibilidad inmediata no al\u00e9rgica. La desensibilizaci\u00f3n permiti\u00f3 continuar el tratamiento con adecuada tolerancia y sin recurrencia. Actualmente se considera repetir las pruebas cut\u00e1neas entre 4 y 6 semanas despu\u00e9s del evento \u00edndice; si son negativas, se plantea realizar una prueba de provocaci\u00f3n a BV. Las pruebas cut\u00e1neas apoyan la seguridad previa a una provocaci\u00f3n controlada. La desensibilizaci\u00f3n es una estrategia eficaz para continuar tratamientos esenciales en oncolog\u00eda pedi\u00e1trica.\nPalabras clave: Desensibilizaci\u00f3n; Anafilaxia; Linfoma de Hodgkin.<\/jats:p>","DOI":"10.29262\/ram.v72i3.1534","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:30:28Z","timestamp":1759242628000},"page":"243","source":"Crossref","is-referenced-by-count":0,"title":["&lt;b&gt;Hipersensibilidad inmediata no al\u00e9rgica a Brentuximab vedotina en pediatr\u00eda: utilidad de las pruebas cut\u00e1neas para guiar prueba de provocaci\u00f3n &lt;\/b&gt;","&lt;b&gt;\u00a0 Non-allergic immediate hypersensitivity to Brentuximab vedotin in pediatrics: usefulness of skin testing to guide provocation testing\u00a0&lt;\/b&gt;"],"prefix":"10.29262","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6761-2688","authenticated-orcid":false,"given":"Karla Daniela","family":"Gonz\u00e1lez Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0157-3321","authenticated-orcid":false,"given":"Pablo","family":"Perea Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1648-8648","authenticated-orcid":false,"given":"Jos\u00e9 Alonso","family":"Guti\u00e9rrez Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"62989","doi-asserted-by":"crossref","unstructured":"Picard M, Galv\u00e3o VR. Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2017;5(3):600-609. doi:10.1016\/j.jaip.2016.12.001","DOI":"10.1016\/j.jaip.2016.12.001"},{"key":"62990","doi-asserted-by":"crossref","unstructured":"DeVita MD, Evens AM, Rosen ST, Greenberger PA, Petrich AM. Multiple successful desensitizations to brentuximab vedotin: a case report and literature review. J Natl Compr Canc Netw. 2014;12(4):465-471. doi:10.6004\/jnccn.2014.0052","DOI":"10.6004\/jnccn.2014.0052"},{"key":"62991","doi-asserted-by":"crossref","unstructured":"V Villarreal-Gonzalez R, N Gonzalez-Diaz S, E de Lira-Quezada C, G\u00f3mez-Almaguer D, G\u00f3mez-De Le\u00f3n A, Acu\u00f1a-Ortega N. Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin's lymphoma. J Oncol Pharm Pract. 2021;27(2):505-508. doi:10.1177\/1078155220942292","DOI":"10.1177\/1078155220942292"},{"key":"62992","doi-asserted-by":"crossref","unstructured":"Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114(2):371-376. doi:10.1016\/j.jaci.2004.04.029","DOI":"10.1016\/j.jaci.2004.04.029"},{"key":"62993","doi-asserted-by":"crossref","unstructured":"Santos RB, Galv\u00e3o VR. Monoclonal Antibodies Hypersensitivity: Prevalence and Management. Immunol Allergy Clin North Am. 2017;37(4):695-711. doi:10.1016\/j.iac.2017.07.003","DOI":"10.1016\/j.iac.2017.07.003"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1534\/2778","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1534\/2778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:30:30Z","timestamp":1759242630000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":5,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v72i3.1534","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}